Selumetinib is a MEK 1/2 inhibitor for the rare disease
News
Almirall buys Allergan’s US dermatology portfolio for $650 million
The deal comprises the brands Aczone, Tazorac, Azelex, Cordran Tape and SeysaraTM
Teva raises earnings estimates despite continuing troubles
Overall revenues were at $4.7 billion, down 18% from the prior year period
The role of the marketer is changing
PharmaTimes talks to Sabina Syed, managing director, Visions4Health and co-chair of the Marketer of the Year steering group about the importance of the competition against an ever changing landscape.
Poll reveals MPs’ attitudes on pharma in Brexit
Only 14% of MPs and 16% of MEPs believe the sector takes priority in negotiations, but both want a greater understanding of pharma’s needs
EMA prepares to scale back more activities ahead of move
Next phase of business continuity plan will launch 1 October at the latest as Agency faces higher-than-expected staff losses
First treatment for lipodystrophy approved in Europe
Aegerion Pharmaceuticals Myalepta approved by EC
Pfizer’s Xeljanz cleared for ulcerative colitis in Europe
Drug becomes the first oral therapy and Janus kinase (JAK) inhibitor available for UC
Boehringer sales rise as Jardiance and Ofev thrive
Prescription drug sales were $7.1 billion for the first half of the year
Biosimilars and key brands drive Pfizer to raise forecasts
Eliquis, Ibrance, Xeljanz and biosimilars help drive profit growth
EC approves Pfizer’s Herceptin biosimilar
Copycat of blockbuster breast cancer drug is Pfizer’s first oncology biosimilar
Sanofi profits and sales fall in Q2
US patent losses continue to sting for the company
Novartis’ migraine drug gets EMA approval
Aimovig becomes Europe’s first treatment specifically designed to prevent migraine
RedHill sees positive results for anti-MAP Crohn’s drug
Drug could be “paradigm shift” in $10 billion industry
Takeda signs antibody therapy deal with HiFiBiO
Companies will research multiple targets in gastrointestinal diseases, cancers and other disorders
